11/8/2018 · DURHAM, N.C. (AP) _ Chimerix Inc. (CMRX) on Thursday reported a loss of $16.1 million in its third quarter. The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.

11/8/2018 · DURHAM, N.C. (AP) _ Chimerix Inc. (CMRX) on Thursday reported a loss of $16.1 million in its third quarter. The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. View detailed financial information, real-time news, videos, quotes and analysis on Chimerix Inc. (NASDAQ:CMRX). Explore commentary on Chimerix Inc. and hear what the What's going on at Chimerix (NASDAQ:CMRX)? View breaking news headlines for CMRX stock from trusted media outlets at MarketBeat. CMRX | Complete Chimerix Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

12/28/2019 · Is Chimerix Inc (CMRX) A Good Stock To Buy? Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell).

Chimerix (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. 3/9/2019 · Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL. 3 Wall Street analysts have issued ratings and price targets for Chimerix in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 96.08%. The high price target for CMRX is $7.00 and the low price target for CMRX is $2.00. acciones auto ayuda bolsa bolsa de ee.uu bolsa de valores bonos capacitación corretaje bursatil crecimiento cursos desarrollo desarrollo personal dinero empleo emprender emprendimiento entrenamientos especulacion exito financiera finanzas forex ganar dinero guía instrumentos financieros internet inversion inversiones invertir la vida libertad

12/8/2019 · Interactive Chart for Chimerix, Inc. (CMRX), analyze all the data with a huge range of indicators.

DE: Deere & Company Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. View Chimerix, Inc. CMRX investment & stock information. Get the latest Chimerix, Inc. CMRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Chimerix (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs.

3/3/2019 · Find the latest Chimerix, Inc. (CMRX) stock quote, history, news and other vital information to help you with your stock trading and investing. 12/23/2019 · Datos gratuitos de la cadena de opciones de CMRX. Precios de compra y venta, análisis y gráfico de posiciones abiertas de Chimerix.

acciones auto ayuda bolsa bolsa de ee.uu bolsa de valores bonos capacitación corretaje bursatil crecimiento cursos desarrollo desarrollo personal dinero empleo emprender emprendimiento entrenamientos especulacion exito financiera finanzas forex ganar dinero guía instrumentos financieros internet inversion inversiones invertir la vida libertad

Get breaking news and analysis on Chimerix, Inc. (CMRX) stock, price quote and chart, trading and investing tools. Ver un gráfico interactivo de valores para Chimerix, Inc. (CMRX) en NASDAQ.com, su fuente de confianza para obtener información y noticias de los mercados. CMRX Real Time Stock Quote - Get Chimerix, Inc. Common Stock (CMRX) last sale data in real-time at NASDAQ.com. Breaking things down more, CMRX is a member of the Medical - Products industry, which includes 86 individual companies and currently sits at #102 in the Zacks Industry Rank. On average, this group has gained an average of 0.42% so far this year, meaning that CMRX is performing better in terms of year-to-date returns. Stock quote for Chimerix, Inc. Common Stock Common Stock (CMRX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. 10/9/2019 · Chimerix (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. 1/3/2020 · CMRX is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for CMRX's full-year earnings has moved 13.18% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. According to our latest data, CMRX has moved about 2.96% on a year-to-date basis.

Iniciar sesión . Iniciar sesión. ¿Olvidaste tu contraseña? ingresar Chimerix Inc. company facts, information and stock details by MarketWatch. View cmrx business summary and other industry information. Chimerex, Inc. (NASDAQ: CMRX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. 12/8/2019 · Interactive Chart for Chimerix, Inc. (CMRX), analyze all the data with a huge range of indicators. 12/13/2019 · Get the latest Chimerix, Inc. (CMRX) stock news and headlines to help you in your trading and investing decisions. 12/10/2019 · Results from a Phase 1 clinical trial evaluating Chimerix's (CMRX-20.6%) dociparstat sodium (DSTAT) in patients with refractory myelodysplastic syndromes